Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Smeenk et al

Saved in:
Bibliographic Details
Main Author: Bi-Cheng Wang
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/7/e011895.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849303617650032640
author Bi-Cheng Wang
author_facet Bi-Cheng Wang
author_sort Bi-Cheng Wang
collection DOAJ
format Article
id doaj-art-cc07db88dfff4b0b95381f13db5051aa
institution Kabale University
issn 2051-1426
language English
publishDate 2025-07-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj-art-cc07db88dfff4b0b95381f13db5051aa2025-08-20T03:56:00ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-07-0113710.1136/jitc-2025-011895Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Smeenk et alBi-Cheng Wang0Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Chinahttps://jitc.bmj.com/content/13/7/e011895.full
spellingShingle Bi-Cheng Wang
Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Smeenk et al
Journal for ImmunoTherapy of Cancer
title Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Smeenk et al
title_full Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Smeenk et al
title_fullStr Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Smeenk et al
title_full_unstemmed Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Smeenk et al
title_short Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Smeenk et al
title_sort correspondence on pembrolizumab hybrid dosing is non inferior to flat dosing in advanced non small cell lung cancer a real world retrospective bicenter cohort study by smeenk et al
url https://jitc.bmj.com/content/13/7/e011895.full
work_keys_str_mv AT bichengwang correspondenceonpembrolizumabhybriddosingisnoninferiortoflatdosinginadvancednonsmallcelllungcancerarealworldretrospectivebicentercohortstudybysmeenketal